

Terms of Reference for the Technical Advisory Group on Pricing Policies for Medicines

A key aspect of universal health coverage is the right of everyone to access safe, quality-assured, effective, and affordable health products, as affirmed by Member States in [Sustainable Development Goal 3.8](#). As medical innovation brings an increasing range of effective medicines and health products, inconsistent availability and poor affordability are rising hurdles for both health systems and the individuals who need them.

WHO has increasingly been requested by Member States for technical input on matters relating to pricing and affordability of health products. These include the [WHO Roadmap for Access to Medicines, Vaccines, and Other Health Products](#) and [World Health Assembly Resolution 72.8 on Improving the transparency of markets for medicines, vaccines, and other health products](#). Most recently the [Expert Committee on Selection and Use of Essential Medicines](#) recommended the establishment of a working group “to provide advice to WHO on policies and rules to make highly priced essential medicines more affordable and accessible” (p.5).

While WHO already convenes the biennial [Fair Pricing Forum](#) with Member States and all relevant stakeholders to discuss the affordability and transparency of prices and costs, there is a recognized need for technical advice to improve equitable and affordable access via evidence-based selection and other pricing policies.

To this effect, the Technical Advisory Group for Pricing Policies for Medicines¹ will support the technical advisory functions of the WHO pricing and affordability programme and scale up the implementation of WHO mandates and guidelines, according to national contexts, to strengthen pricing policies, transparency of markets, and affordable access.

I. Functions

In its capacity as an advisory body to WHO, the technical advisory group (TAG) shall have the following functions:

1. *To provide evidence-based technical advice to guide efforts to increase affordable access to essential and priority medicines and health products;*
2. *To advise WHO on the implementation of medicines pricing policies, emerging evidence, and good practices for improving the affordability of essential medicines;*
3. *To advise WHO on methods for measuring availability and pricing of medicines, and the impact of interventions to make medicines more affordable;*
4. *To advise WHO on further research, country support, and international collaboration needed to improve the transparency of markets for medicines; and*
5. *To advise WHO on stakeholder engagement to improve the affordability of medicines.*

¹ The Technical Advisory Committee Group on request of the WHO Secretariat may also perform any of the stated functions for essential health products as identified in the request of the Secretariat.

II. **Composition**

1. The TAG shall have up to 20 members², who shall serve in their personal capacities to represent the broad range of disciplines relevant to pricing and affordability of medicines. In the selection of the TAG members, consideration shall be given to attaining an adequate distribution of technical expertise, geographical representation, and gender balance.
2. Members of the TAG, including the Chairperson, shall be selected and appointed by WHO following an open call for experts. The Chairperson's functions include the following:
 - to chair the meeting of the TAG;
 - to liaise with the WHO Secretariat between meetings.

In appointing a Chairperson, consideration shall be given to gender and geographical representation.

3. Members of the TAG shall be appointed to serve for a period of 2 years and shall be eligible for reappointment. A Chairperson is eligible for reappointment as a member of the TAG, but is only permitted to serve as Chairperson for one term. Their appointment and/or designation as Chairperson may be terminated at any time by WHO if WHO's interest so requires or, as otherwise specified in these terms of reference or letters of appointment. Where a member's appointment is terminated, WHO may decide to appoint a replacement member.
4. TAG members must respect the impartiality and independence required of WHO. In performing their work, members may not seek or accept instructions from any Government or from any authority external to the Organization. They must be free of any real, potential or apparent conflicts of interest. To this end, proposed members/members shall be required to complete a declaration of interests form and their appointment, or continuation of their appointment, shall be subject to the evaluation of completed forms by the WHO Secretariat, determining that their participation would not give rise to a real, potential or apparent conflict of interest.
5. Following a determination that a proposed member's participation in the TAG would not give rise to a real, potential or apparent conflict of interest, the proposed member will be sent a letter inviting them to be a member of the TAG. Their appointment to the TAG is subject to WHO receiving the countersigned invitation letter and letter of agreement. Notwithstanding the requirement to complete the WHO declaration of interest form, TAG members have an ongoing obligation to inform the WHO of any interests real or perceived that may give rise to a real, potential or apparent conflict of interest.

² Members serve as full participants and partake in the decision-making process of the meeting in which they are involved.

6. As contemplated in paragraph II.4 above, WHO may, from time to time, request TAG members to complete a new declaration of interest form. This may be before a TAG meeting or any other TAG-related activity or engagement, as decided by WHO. Where WHO has made such a request, the TAG member's participation in the TAG activity or engagement is subject to a determination that their participation would not give rise to a real, potential or apparent conflict of interest.
7. Where a TAG member is invited by WHO to travel to an in-person TAG meeting, WHO shall, subject to any conflict of interest determination as set out in paragraph II.6 above, issue a letter of appointment as a temporary adviser and accompanying memorandum of agreement (together 'Temporary Adviser Letter'). WHO shall not authorize travel by an TAG member, until it receives a countersigned Temporary Adviser Letter.
8. TAG members do not receive any remuneration from the Organization for any work related to the TAG. However, when attending in-person meetings at the invitation of WHO, their travel cost and per diem shall be covered by WHO in accordance with the applicable WHO rules and policies.

III. Operation

1. The TAG shall normally meet [at least once] each year. However, WHO may convene additional meetings. TAG meetings may be held in person (at WHO headquarters in Geneva or another location, as determined by WHO) or virtually, via video or teleconference.

TAG meetings may be held in open and/or closed session, as decided by the Chairperson in consultation with WHO.

- (a) Open sessions: Open sessions shall be convened for the sole purpose of the exchange of non-confidential information and views and may be attended by Observers (as defined in paragraph III.3 below).
 - (b) Closed sessions: The sessions dealing with the formulation of recommendations and/or advice to WHO shall be restricted to the members of the TAG and essential WHO Secretariat staff.
2. The quorum for TAG meetings shall be two thirds of the members.
3. WHO may, at its sole discretion, invite external individuals from time to time to attend the open sessions of an advisory group, or parts thereof, as "observers". Observers may be invited either in their personal capacity, or as representatives from a governmental institution / intergovernmental organization, or from a non-State actor. WHO will request observers invited in their personal capacity to complete a confidentiality undertaking and a declaration of interests form prior to attending a session of the advisory group. Invitations to observers attending as representatives from non-State actors will be subject to WHO internal due diligence and risk assessment including conflict of interest considerations in accordance with the Framework for engagement with non-State actors (FENSA). Observers invited as representatives may also be requested to complete a confidentiality undertaking. Observers

shall normally attend meetings of the TAG at their own expense and be responsible for making all arrangements in that regard.

At the invitation of the Chairperson, observers may be asked to present their personal views and/or the policies of their organization. Observers will not participate in the process of adopting recommendations of the TAG.

4. The TAG may decide to establish smaller working groups (sub-groups of the TAG) to work on specific issues. Their deliberations shall take place via teleconference or video-conference. For these sub-groups, no quorum requirement will apply; the outcome of their deliberations will be submitted to the TAG for review at one of its meetings.
5. TAG members are expected to attend meetings without seeking to be represented by other nominated person(s). If a member misses two consecutive meetings, WHO may end his/her appointment as a member of the TAG.
6. Reports of each meeting shall be submitted by the TAG to WHO (the Assistant Director-General of the responsible Division). All recommendations from the TAG are advisory to WHO, who retains full control over any subsequent decisions or actions regarding any proposals, policy issues or other matters considered by the TAG.
7. The TAG shall normally make recommendations by consensus. If, in exceptional circumstances, a consensus on a particular issue cannot be reached, minority opinions will be reflected in the meeting report.
8. Active participation is expected from all TAG members, including in working groups, teleconferences, and interaction over email. TAG members may, in advance of TAG meetings, be requested to review meeting documentation and to provide their views for consideration by the TAG.
9. WHO shall determine the modes of communication by the TAG, including between WHO and the TAG members, and the TAG members among themselves.
10. TAG members shall not speak on behalf of, or represent, the TAG or WHO to any third party.

IV. Secretariat

WHO shall provide the secretariat for the TAG, including necessary scientific, technical, administrative, and other support. In this regard, the WHO Secretariat shall provide the members in advance of each meeting with the agenda, working documents and discussion papers. Distribution of the aforesaid documents to Observers will be determined by the WHO Secretariat. The meeting agenda shall include details such as: whether a meeting, or part thereof, is closed or open; and whether Observers are permitted to attend.

V. Information and documentation

1. Information and documentation to which members may gain access in performing TAG related activities shall be considered as confidential and proprietary to WHO and/or parties collaborating with WHO. In addition, by counter signing the letter of appointment and the accompanying terms and conditions referred to in section II(5) above, TAG members undertake to abide by the confidentiality obligations contained therein and also confirm that any and all rights in the work performed by them in connection with, or as a result of their TAG-related activities shall be exclusively vested in WHO.
2. TAG members and Observers shall not quote from, circulate, or use TAG documents for any purpose other than in a manner consistent with their responsibilities under these Terms of Reference.
3. WHO retains full control over the publication of the reports of the TAG, including deciding whether or not to publish them.